Clinical trials: Cancer Stem Cells
Lymphoma
Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Stem cell factor may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system…
- Trial name
- NCT00058045
- Testing
- aldesleukin, recombinant human stem cell factor
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Roswell Park Cancer Institute
Neoplasm, Pancreas
Side Population in Pancreatic Ductal Adenocarcinoma (PDAC)
In the current project we aim to study the oncological process of pancreatic cancer, from a perspective of the CSC-theory and in particular through the 'side population' (SP)-approach.
- Trial name
- NCT00936104
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- University Hospital, Gasthuisberg
Neuroblastoma
Chemotherapy and Surgery Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs to kill…
- Trial name
- NCT00024193
- Testing
- filgrastim, busulfan, cisplatin
- Where
- France
- Sponsor
- Children's Cancer and Leukaemia Group
Acute Lymphoblastic Leukemia (ALL)
Potential Role of CD9 and Implication of Motility Process in Pathogenesis of TEL/ALM1-positive ALL Relapses (LAL TEL/ALM1 and CD9).
Down regulation of CD9 in TEL/AML1-positive ALL is addressed in motility assays to explore its role in B-ALL pathogenesis and its potential implication in relapses (and prognosis).
- Trial name
- LAL TEL/ALM1 (NCT01282593)
- Testing
- Impact of CD9 expression level on motility assays, Post-transcriptional regulation of CD9
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Rennes University Hospital
Hematopoietic Stem Cell Transplantation (HSCT)
Prehabilitation to Improve Frailty, Function, and Quality of Life in Candidates for Hematopoietic Stem Cell Transplantation
Candidates for hematopoietic stem cell transplantation (HSCT) frequently experience declines in strength, physical function, and quality of life before the procedure.
- Trial name
- PREHAB-HSCT (NCT07255521)
- Testing
- Multimodal Prehabilitation
- Where
- 2 sites in Chile
- Volunteers
- 68 people
- Sponsor
- Hospital del Salvador
Leukemia
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
Primary Objective: To estimate the probability of molecular complete remission at one year for the described sequential treatment approach, with nonablative hematopoietic transplantation, post transplant imatinib mesylate and…
- Trial name
- NCT00499889
- Testing
- Imatinib Mesylate, Fludarabine (Fludara), Busulfan
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Contrast-enhanced abdominal CT will be performed 1-2 weeks after allogeneic stem cell transplant, and radiographic evidence of mucosal inflammation will be correlated with the subsequent development of acute graft versus host…
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic, Multiple Myeloma
- Trial name
- GVHD (NCT02117115)
- Testing
- Dynamic contrast-enhanced computed tomography, Ioversol
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Lymphoma, Large-Cell, Diffuse
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
This study is being conducted to compare the efficacy and safety of ofatumumab in addition to salvage chemotherapy versus rituximab in addition to salvage chemotherapy in CD20 positive DLBCL subjects relapsing, or with persistent…
- Trial name
- ORCHARRD (NCT01014208)
- Testing
- OFATUMUMAB + DHAP, RITUXIMAB + DHAP
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 447 people
- Sponsor
- GlaxoSmithKline
Myelodysplastic Syndrome (MDS), Chronic Myelogenous Leukemia
Improving Blood Stem Cell Collection and Transplant Procedures
Background: People who have some kinds of cancer can benefit from donated bone marrow stem cells. These stem cells help produce healthy bone marrow and slow or stop the spread of abnormal cells.
- Conditions
- Myelodysplastic Syndrome (MDS), Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, CML (Chronic Myelogenous Leukemia
- Trial name
- NCT01517035
- Testing
- Stem Cell Transplantation
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myeloma
Feasibility of Pre Transplant Exercise (Pre-habilitation) for Multiple Myeloma Patients Awaiting Autologous Stem Cell Transplantation
The investigators propose to determine whether it is acceptable to patients with a diagnosis of multiple myeloma (a type of blood cancer that can cause bone weakness, pain and fatigue) to be offered and attend an exercise group…
- Trial name
- PREeMPT (NCT03135925)
- Testing
- Supervised Exercise Program
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Multiple Myeloma
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
The main purpose of this study is to see how well a new treatment ramantamig-D works compared to standard treatments that is either DVRd or DRd on progression-free survival (PFS; time until a participant's disease worsens) and…
- Trial name
- TRIlogy-7 (NCT07665450)
- Testing
- Ramantamig, Daratumumab, Lenalidomide
- Where
- 103 sites in Australia, Czechia and 12 more
- Volunteers
- 1,000 people
- Sponsor
- Janssen Research & Development, LLC
Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma
Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
This phase II trial studies how well ibritumomab tiuxetan before donor peripheral blood stem cell transplant works in treating patients with relapsed or refractory non-Hodgkin lymphoma.
- Trial name
- NCT01811368
- Testing
- rituximab, ibritumomab tiuxetan, anti-thymocyte globulin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Joseph Tuscano
COVID-19
Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19
Early Mild Outpatient infusion Therapy with ExoFloTM for COVID-19 (EMOTE COVID-19) To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles…
- Trial name
- NCT05125562
- Testing
- ExoFlo
- Sponsor
- Direct Biologics, LLC
Multiple Myeloma
A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care
This study aims to compare how belantamab behaves in the body when given as an injection under the skin (SC) versus into a vein (IV) in participants with multiple myeloma who are receiving standard of care treatment, to enable…
- Trial name
- DynaMMic-2 (NCT07742527)
- Testing
- Belantamab SC, Belantamab IV, Recombinant Human Hyaluronidase PH20 (rHuPH20)
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
To provide the IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma
- Trial name
- NCT01890486
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Wake Forest University Health Sciences
Light Chain Deposition Disease, Primary Systemic Amyloidosis
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
This randomized phase III trial is studying melphalan and dexamethasone to see how well they work with or without bortezomib in treating patients with previously untreated systemic amyloidosis.
- Trial name
- NCT01078454
- Testing
- melphalan, dexamethasone, bortezomib
- Where
- 209 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who…
- Trial name
- KarMMa-9 (NCT06045806)
- Testing
- idecabtagene vicleucel, Lenalidomide, Fludarabine
- Where
- 101 sites in United States, Australia and 16 more
- Volunteers
- 79 people
- Sponsor
- Celgene
Chronic Lymphocytic Leukemia
Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation
Background: After allogeneic (donor) stem cell transplantation, a new immune system grows in the patient from the transplanted donor stem cells and lymphocytes (type of immune cell).
- Trial name
- NCT01445132
- Testing
- Allogeneic Cell Therapy w/ Tumor-derived Lypho
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Malignancies
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
The goal of this clinical research study is to learn if intermediate-intensity conditioning therapy followed by a cord blood transplant can help to control high-risk hematological malignancies in patients who need a second…
- Trial name
- NCT06807606
- Testing
- Drugs Cyclophosphamide, Fludarabine, Thiotepa
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as temozolomide, vincristine, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00138216
- Testing
- irinotecan hydrochloride, temozolomide, vincristine sulfate
- Where
- 18 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Children's Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.